India · Delayed Price · Currency is INR NSE:SUNPHARMA Statistics
Total Valuation
NSE:SUNPHARMA has a market cap or net worth of INR 4.25 trillion. The enterprise value is 3.95 trillion.
| Market Cap | 4.25T |
| Enterprise Value | 3.95T |
Important Dates
The last earnings date was Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Jul 7, 2026 |
Share Statistics
NSE:SUNPHARMA has 2.40 billion shares outstanding. The number of shares has decreased by -0.10% in one year.
| Current Share Class | 2.40B |
| Shares Outstanding | 2.40B |
| Shares Change (YoY) | -0.10% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 21.73% |
| Owned by Institutions (%) | 28.94% |
| Float | 831.71M |
Valuation Ratios
The trailing PE ratio is 38.80 and the forward PE ratio is 30.53. NSE:SUNPHARMA's PEG ratio is 1.98.
| PE Ratio | 38.80 |
| Forward PE | 30.53 |
| PS Ratio | 6.90 |
| PB Ratio | 4.75 |
| P/TBV Ratio | 6.51 |
| P/FCF Ratio | 54.74 |
| P/OCF Ratio | 39.47 |
| PEG Ratio | 1.98 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.96, with an EV/FCF ratio of 50.87.
| EV / Earnings | 36.06 |
| EV / Sales | 6.42 |
| EV / EBITDA | 22.96 |
| EV / EBIT | 27.68 |
| EV / FCF | 50.87 |
Financial Position
The company has a current ratio of 2.94, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.94 |
| Quick Ratio | 2.18 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.19 |
| Debt / FCF | 0.42 |
| Interest Coverage | 42.34 |
Financial Efficiency
Return on equity (ROE) is 13.10% and return on invested capital (ROIC) is 18.40%.
| Return on Equity (ROE) | 13.10% |
| Return on Assets (ROA) | 8.20% |
| Return on Invested Capital (ROIC) | 18.40% |
| Return on Capital Employed (ROCE) | 15.71% |
| Weighted Average Cost of Capital (WACC) | 5.00% |
| Revenue Per Employee | 13.11M |
| Profits Per Employee | 2.33M |
| Employee Count | 47,000 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 1.11 |
Taxes
In the past 12 months, NSE:SUNPHARMA has paid 39.99 billion in taxes.
| Income Tax | 39.99B |
| Effective Tax Rate | 26.69% |
Stock Price Statistics
The stock price has increased by +3.93% in the last 52 weeks. The beta is 0.13, so NSE:SUNPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | +3.93% |
| 50-Day Moving Average | 1,826.95 |
| 200-Day Moving Average | 1,808.84 |
| Relative Strength Index (RSI) | 46.83 |
| Average Volume (20 Days) | 1,931,323 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:SUNPHARMA had revenue of INR 616.31 billion and earned 109.66 billion in profits. Earnings per share was 45.71.
| Revenue | 616.31B |
| Gross Profit | 488.90B |
| Operating Income | 143.37B |
| Pretax Income | 149.87B |
| Net Income | 109.66B |
| EBITDA | 171.05B |
| EBIT | 143.37B |
| Earnings Per Share (EPS) | 45.71 |
Balance Sheet
The company has 335.70 billion in cash and 32.41 billion in debt, with a net cash position of 303.29 billion or 126.41 per share.
| Cash & Cash Equivalents | 335.70B |
| Total Debt | 32.41B |
| Net Cash | 303.29B |
| Net Cash Per Share | 126.41 |
| Equity (Book Value) | 895.64B |
| Book Value Per Share | 372.65 |
| Working Capital | 456.75B |
Cash Flow
In the last 12 months, operating cash flow was 107.80 billion and capital expenditures -30.06 billion, giving a free cash flow of 77.73 billion.
| Operating Cash Flow | 107.80B |
| Capital Expenditures | -30.06B |
| Depreciation & Amortization | 27.69B |
| Net Borrowing | -23.67B |
| Free Cash Flow | 77.73B |
| FCF Per Share | 32.40 |
Margins
Gross margin is 79.33%, with operating and profit margins of 23.26% and 17.79%.
| Gross Margin | 79.33% |
| Operating Margin | 23.26% |
| Pretax Margin | 24.32% |
| Profit Margin | 17.79% |
| EBITDA Margin | 27.75% |
| EBIT Margin | 23.26% |
| FCF Margin | 12.61% |
Dividends & Yields
This stock pays an annual dividend of 16.00, which amounts to a dividend yield of 0.90%.
| Dividend Per Share | 16.00 |
| Dividend Yield | 0.90% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 7 |
| Payout Ratio | 34.78% |
| FCF Payout Ratio | 49.39% |
| Buyback Yield | 0.10% |
| Shareholder Yield | 1.00% |
| Earnings Yield | 2.58% |
| FCF Yield | 1.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:SUNPHARMA is 2,128.70, which is 20.04% higher than the current price. The consensus rating is "Buy".
| Price Target | 2,128.70 |
| Price Target Difference | 20.04% |
| Analyst Consensus | Buy |
| Analyst Count | 34 |
| Revenue Growth Forecast (3Y) | 10.88% |
| EPS Growth Forecast (3Y) | 11.32% |
Stock Splits
The last stock split was on July 29, 2013. It was a forward split with a ratio of 2.
| Last Split Date | Jul 29, 2013 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |